Glanbia Plc · EURONEXT:GL9
Glanbia — Glanbia Plc Ord — H1 2025 Earnings Presentation
21 slides from Glanbia's earnings presentation, Aug 13, 2025
Slide 1: Half Year 2025 Results
H A L F Y E A R 2 0 2 5 R E S U LT S 13 AUGUST 2025 Hugh McGuire Mark Garvey Chief Executive Officer Chief Financial Officer
Slide 2: Important Notice
I M P O R T A N T N O T I C E This presentation contains forward-looking statements. These statements have been made by the Directors in good faith based on the information available to them up to the time of their approval of this presentation. Due to the inherent uncertainties, including both econ
Slide 3: Agenda
Agenda 1 B U S I N E S S R E V I E W F I N A N C E 2 R E V I E W 3 Q & A 3 | Glanbia PLC HY Results 2025
Slide 4: Highlights
HIGHLIGHTS HY 2025 H1 2025 Group performance ahead of expectations with adjusted EPS of 63.03 $cent with strong momentum in Health & Nutrition and Dairy Nutrition Optimum Nutrition volume and price growth in Q2 showing sequential improvement through the period Continued progress on Group-wide transf
Slide 5: Business Review
1 BUSINESS REVIEW Hugh McGuire Chief Executive Officer 5 | Glanbia PLC HY Results 2025
Slide 6: Performance Nutrition (PN)
PERFORMANCE NUTRITION (PN) Improved performance in the second quarter $m HY25 Growth%1 Revenue 850.0 (3.8%) EBITDA 108.2 (30.5%) EBITDA margin 12.7% (490bps) • LFL2 revenue -3.8%: volume -3.5%, pricing -0.3% • -1.5% excluding SlimFast and Body & Fit % of PN Revenue 67% 19% • -8.7% in Americas with d
Slide 7: World's #1 Sports Nutrition Brand With Revenue Growth In Q2
WORLD’S #1 SPORTS NUTRITION BRAND WITH REVENUE GROWTH IN Q2 World’s leading sports Continued progress on nutrition brand innovation LFL US growth1 consumption2 (0.5%) +1.0% Volume decline of -0.5% driven by US club and specialty channels, somewhat offset with good growth in international markets and
Slide 8: Healthy Lifestyle Brands Continuing To Focus On Innovation
H E A LT H Y L I F E S T Y L E B R A N D S C O N T I N U I N G T O F O C U S O N I N N O VAT I O N Isopure Whey Protein Isolate & Isopure Protein Water Collagen launched in the UK launching in Q3 LFL US growth1 consumption2 +0.6% (5.8%) LFL revenue +0.6% driven by double-digit growth in Isopure part
Slide 9: Health & Nutrition (H&N)
H E A LT H & N U T R I T I O N ( H & N ) Strong topline growth and margin expansion through premix and flavours $m HY25 Growth%1 Revenue 313.0 +18.0% EBITDA 60.9 +35.9% EBITDA margin 19.5% +260bps • LFL2 revenue +6.5%: volume +6.9%, pricing –0.4% • Volume increase driven by strong growth in both pre
Slide 10: H&N – Key Platform For Growth
H & N – K E Y P L AT F O R M F O R G R O W T H Operating in attractive end-use markets with opportunity for organic and inorganic expansion Strong position in Driven by strong trends Supported by acquisitions key ingredients in end use markets and capital investment Vitamins, Minerals & ▪ Acquisitio
Slide 11: Dairy Nutrition (DN)
D A I RY N U T R I T I O N ( D N ) Strong performance through volume and pricing $m HY25 Growth%1 Revenue 763.7 +14.1% EBITDA 72.2 +19.5% EBITDA margin 9.5% +50bps • LFL2 +14.1%: volume +4.3%, pricing +9.8% • Strong demand for whey protein driven by the RTM, RTE and RTD segments • Volume increase dr
Slide 12: Group-Wide Transformation Programme
G R O U P - W I D E T R A N S F O R M AT I O N P R O G R A M M E Continued progress on the Group-wide transformation programme, driving change through streamlined focus HY 2025 PROGRESS Operating model Unlocking efficiencies Digital transformation Portfolio optimisation Outsourcing of key HR and Dai
Slide 13: Finance Review
2 FINANCE REVIEW Mark Garvey Chief Financial Officer 13 | Glanbia PLC HY Results 2025
Slide 14: HY Financial Summary
H Y 2 0 2 5 F I N A N C I A L S U M M A RY $1.9bn REVENUE +6.0% constant currency increase $241m EBITDA -7.5% constant currency decline EBITDA 180bps constant currency vs. HY 2024 decrease 12.5% M ARGIN PN -490bps and H&N +260bps constant currency ADJUSTED 63.03$c EPS -7.5% constant currency decline
Slide 15: Strong Balance Sheet
STRONG BALANCE SHEET DEBT CAPITAL SHAREHOLDER EXPENDITURE RETURNS Net Debt $650 million HY25 capex of $47.7m Interim dividend increased by 10% Total committed facilities of FY25 capex expected to $1.37bn be $80m – $90m €62.8m returned via share buybacks to date1 Net debt to adjusted EBITDA of 1.28 t
Slide 16: Other Financial Matters
O T H E R F I N A N C I A L M AT T E R S EXCEPTIONAL Charges of $32.6m largely related to Group-wide transformation ITEMS programme NET FINANCE COSTS Increase of $3.2m mainly driven by a reduction in interest income INCOME TAX Expected rate for FY 2025 of 14% to 16% JOINT VENTURES Decrease of $0.3m
Slide 17: 2025 Outlook
2025 OUTLOOK Upgrading 2025 adjusted EPS guidance as a result of increased revenue momentum in PN and improved margins in H&N Revenue Earnings Capital growth growth allocation PN LFL revenue1 growth of PN EBITDA margin 13% – 14% OCF conversion 80%+ +2-3% H&N EBITDA margin2 18% – 19% €50m buyback ong
Slide 18: Delivering Better Nutrition
DELIVERING BETTER NUTRITION Positioned for long-term growth 1 Improving trends within Performance Nutrition and continued strong demand within Health & Nutrition 2 Transformation programme ongoing to drive efficiencies across the Group and support the next phase of growth 3 Focused on long-term grow
Slide 19: A Performance Driven Purpose Led Global Nutrition Company
A PERFORMANCE DRIVEN PURPOSE L E D G L O B A L N U T R I T I O N C O M PA N Y 19 | Glanbia PLC HY Results 2025
Slide 20: Appendices
A APPENDICES 20 | Glanbia PLC HY Results 2025
Slide 21: PN HY Revenue Overview
P N H Y 2 0 2 5 R E V E N U E O V E RV I E W 4% 11% 8% 39% 35% 9% 20% BY BY BY REGION CHANNEL F O R M AT 61% 79% 34% L F L G R O W T H 1: Americas -8.7% Online +12.6% Powders -2.4% International +4.9% FDMC -9.2% RTE -8.8% Distributor -14.4% RTD -13.5% Specialty -9.7% Other +2.7% 21 | Glanbia PLC HY